PGGT1B

Summary

PGGT1B (protein geranylgeranyltransferase type I subunit beta, HGNC:8895) is a protein-coding gene on chromosome 5q22.3, encoding Geranylgeranyl transferase type-1 subunit beta (P53609). Catalyzes the transfer of a geranyl-geranyl moiety from geranyl-geranyl pyrophosphate to a cysteine at the fourth position from the C-terminus of proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. It is a selective cancer dependency (DepMap: 30.9% of cell lines).

Protein geranylgeranyltransferase type I (GGTase-I) transfers a geranylgeranyl group to the cysteine residue of candidate proteins containing a C-terminal CAAX motif in which ‘A’ is an aliphatic amino acid and ‘X’ is leucine (summarized by Zhang et al., 1994 [PubMed 8106351]). The enzyme is composed of a 48-kD alpha subunit (FNTA; MIM 134635) and a 43-kD beta subunit, encoded by the PGGT1B gene. The FNTA gene encodes the alpha subunit for both GGTase-I and the related enzyme farnesyltransferase.

Source: NCBI Gene 5229 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 41 total
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 30.9% of screened cell lines
• MANE Select transcript: NM_005023

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8895
Approved symbol	PGGT1B
Name	protein geranylgeranyltransferase type I subunit beta
Location	5q22.3
Locus type	gene with protein product
Status	Approved
Aliases	GGTI, BGGI
Ensembl gene	ENSG00000164219
Ensembl biotype	protein_coding
OMIM	602031
Entrez	5229

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 2 protein_coding_CDS_not_defined, 2 protein_coding, 1 retained_intron

ENST00000296642, ENST00000379615, ENST00000419445, ENST00000503638, ENST00000514178

RefSeq mRNA: 1 — MANE Select: NM_005023 NM_005023

CCDS: CCDS4116

Canonical transcript exons

ENST00000419445 — 9 exons

Exon	Start	End
ENSE00001082573	115253137	115253255
ENSE00001316610	115204012	115212583
ENSE00001521927	115262712	115262877
ENSE00003505269	115237858	115238009
ENSE00003604722	115221824	115222008
ENSE00003610147	115241539	115241606
ENSE00003616939	115216865	115216973
ENSE00003651354	115236390	115236522
ENSE00003671772	115230976	115231021

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 95.47.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.2111 / max 71.7681, expressed in 1429 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
62997	3.2111	1429

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	95.47	gold quality
secondary oocyte	CL:0000655	92.67	gold quality
adrenal tissue	UBERON:0018303	89.97	gold quality
monocyte	CL:0000576	89.95	gold quality
mononuclear cell	CL:0000842	89.79	gold quality
palpebral conjunctiva	UBERON:0001812	89.60	gold quality
leukocyte	CL:0000738	89.40	gold quality
mucosa of sigmoid colon	UBERON:0004993	89.39	gold quality
colonic mucosa	UBERON:0000317	89.17	gold quality
calcaneal tendon	UBERON:0003701	87.43	gold quality
esophagus squamous epithelium	UBERON:0006920	87.20	gold quality
rectum	UBERON:0001052	86.87	gold quality
islet of Langerhans	UBERON:0000006	86.72	gold quality
amniotic fluid	UBERON:0000173	86.28	gold quality
colonic epithelium	UBERON:0000397	86.21	gold quality
ventricular zone	UBERON:0003053	86.04	gold quality
bronchial epithelial cell	CL:0002328	86.03	gold quality
epithelium of nasopharynx	UBERON:0001951	85.99	gold quality
oral cavity	UBERON:0000167	85.90	gold quality
jejunal mucosa	UBERON:0000399	85.72	gold quality
endothelial cell	CL:0000115	84.74	gold quality
ganglionic eminence	UBERON:0004023	84.61	gold quality
tonsil	UBERON:0002372	84.47	gold quality
bone marrow	UBERON:0002371	84.31	gold quality
gingival epithelium	UBERON:0001949	84.09	gold quality
gingiva	UBERON:0001828	83.57	gold quality
epithelium of esophagus	UBERON:0001976	83.34	gold quality
bone marrow cell	CL:0002092	83.14	gold quality
germinal epithelium of ovary	UBERON:0001304	82.95	gold quality
pigmented layer of retina	UBERON:0001782	82.64	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.97

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

115 targeting PGGT1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 30.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 6)

• results suggest that geranylgeranylation of RhoA is critical for cancer cell invasion (PMID:14598891)
• Results suggest that all peptide substrates adopt a common binding mode in the protein farnesyltransferase and geranylgeranyltransferase active site. (PMID:15451670)
• RNAi knockdown of GGTase-Ibeta inhibited invasion, disrupted F-actin organization and decreased the level of cofilin in PC-3 cells. (PMID:20446922)
• our findings identify Geranylgeranyl transferase 1 as a key regulator of human airway smooth muscle cell viability (PMID:22160308)
• our study showed, for the first time, that HIF-1alpha was regulated by protein prenylation transferase GGTI and mediated the effect of GGTI on glioma cell migration and invasion (PMID:23475391)
• The diagnostic significance of PGGT1B in psoriasis. (PMID:33548109)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	pggt1b	ENSDARG00000103464
mus_musculus	Pggt1b	ENSMUSG00000024477
rattus_norvegicus	Pggt1b	ENSRNOG00000003541
drosophila_melanogaster	betaggt-I	FBGN0015000

Paralogs (2): RABGGTB (ENSG00000137955), FNTB (ENSG00000257365)

Protein

Protein identifiers

Geranylgeranyl transferase type-1 subunit beta — P53609 (reviewed: P53609)

Alternative names: Geranylgeranyl transferase type I subunit beta, Type I protein geranyl-geranyltransferase subunit beta

All UniProt accessions (1): P53609

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the transfer of a geranyl-geranyl moiety from geranyl-geranyl pyrophosphate to a cysteine at the fourth position from the C-terminus of proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. Known substrates include RAC1, RAC2, RAP1A and RAP1B.

Subunit / interactions. Heterodimer of FNTA and PGGT1B. PGGT1B mediates interaction with substrate peptides.

Cofactor. Binds 1 zinc ion per subunit.

Similarity. Belongs to the protein prenyltransferase subunit beta family.

Isoforms (2)

UniProt ID	Names	Canonical?
P53609-1	1	yes
P53609-2	2

RefSeq proteins (1): NP_005014* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001330	Prenyltrans	Domain
IPR008930	Terpenoid_cyclase/PrenylTrfase	Homologous_superfamily
IPR041960	GGTase_I_beta	Family
IPR045089	PGGT1B-like	Family

Pfam: PF00432

Enzyme classification (BRENDA):

• EC 2.5.1.59 — protein geranylgeranyltransferase type I (BRENDA: 18 organisms, 93 substrates, 119 inhibitors, 28 Km, 32 kcat entries)

Substrate kinetics (BRENDA)

31 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GERANYLGERANYL DIPHOSPHATE	—	5
(BIOTIN-CONH-(CH2)5-CO-)-NPFREKKFFCAI-LEU	0.0003–0.025	3
DANSYL-GLY-CYS-ILE-ILE-LEU	0.0018–0.0024	2
RAS-CYS-VAL-LEU-LEU	0.0009–0.0012	2
3,7,11-TRIMETHYL-12-(7-NITRO-BENZO[1,2,5]-OXADIA	—	1
ARG-ARG-CYS-VAL-LEU-LEU	—	1
ASP-ASP-PRO-THR-ALA-SER-ALA-CYS-VAL-LEU-LEU	—	1
GST-CDC42	0.016	1
GST-RHOA	0.042	1
KI-RAS4A	0.0088	1
KI-RAS4B	0.012	1
LYS-LYS-CYS-ILE-ILE-MET	0.0001	1
LYS-PRO-CYS-VAL-VAL-MET	0.002	1
N-RAS	0.0021	1
PHE-PHE-CYS-ALA-ILE-LEU	0.002	1

Catalyzed reactions (Rhea), 1 shown:

• geranylgeranyl diphosphate + L-cysteinyl-[protein] = S-geranylgeranyl-L-cysteinyl-[protein] + diphosphate (RHEA:21240)

UniProt features (15 total): binding site 6, repeat 4, sequence conflict 2, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P53609-F1	94.68	0.91

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 321; 219–221; 263–266; 269; 271; 272–275

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9953170	GBP-mediated host defense

MSigDB gene sets: 141 (showing top): REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, AAGCCAT_MIR135A_MIR135B, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, WANG_RECURRENT_LIVER_CANCER_DN, GATA1_04, SCHLOSSER_SERUM_RESPONSE_DN, GATA1_03, MILI_PSEUDOPODIA_CHEMOTAXIS_UP, CUI_TCF21_TARGETS_2_DN, AP4_01, GOCC_TRANSFERASE_COMPLEX, LIU_SOX4_TARGETS_DN, GOMF_PRENYLTRANSFERASE_ACTIVITY, JOHNSTONE_PARVB_TARGETS_3_DN, GOBP_PROTEIN_GERANYLGERANYLATION

GO Biological Process (1): protein geranylgeranylation (GO:0018344)

GO Molecular Function (9): protein geranylgeranyltransferase activity (GO:0004661), CAAX-protein geranylgeranyltransferase activity (GO:0004662), zinc ion binding (GO:0008270), catalytic activity (GO:0003824), prenyltransferase activity (GO:0004659), protein binding (GO:0005515), protein prenyltransferase activity (GO:0008318), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (1): CAAX-protein geranylgeranyltransferase complex (GO:0005953)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Antimicrobial mechanism of IFN-stimulated genes	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein prenylation	1
protein prenyltransferase activity	1
protein geranylgeranyltransferase activity	1
transition metal ion binding	1
molecular_function	1
transferase activity, transferring alkyl or aryl (other than methyl) groups	1
binding	1
prenyltransferase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
cation binding	1
intracellular protein-containing complex	1
transferase complex	1

Protein interactions and networks

STRING

566 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PGGT1B	FNTA	P49354	986
PGGT1B	RABGGTA	Q92696	764
PGGT1B	ICMT	O60725	495
PGGT1B	RCE1	Q9Y256	486
PGGT1B	RAP1A	P10113	476
PGGT1B	HRAS	P01112	456
PGGT1B	PAN3	Q58A45	455
PGGT1B	FNTB	P49356	430
PGGT1B	HMGCR	P04035	409
PGGT1B	DIXDC1	Q155Q3	407
PGGT1B	FDPS	P14324	406
PGGT1B	GGPS1	O95749	391
PGGT1B	ZMPSTE24	O75844	388
PGGT1B	GART	P22102	353
PGGT1B	SAMM50	Q9Y512	350

IntAct

33 interactions, top by confidence:

A	B	Type	Score
FNTA	FNTB	psi-mi:“MI:0914”(association)	0.960
FNTA	PGGT1B	psi-mi:“MI:0915”(physical association)	0.840
TSKS	RGPD8	psi-mi:“MI:0914”(association)	0.530
AMMECR1L	FNTA	psi-mi:“MI:0914”(association)	0.530
HEYL	PGGT1B	psi-mi:“MI:0914”(association)	0.530
PGGT1B	FNTA	psi-mi:“MI:0915”(physical association)	0.370
FNTA	PGGT1B	psi-mi:“MI:0915”(physical association)	0.370
SRGAP3	CCDC85C	psi-mi:“MI:0914”(association)	0.350
AMMECR1L	FNTA	psi-mi:“MI:0914”(association)	0.350
HEYL	FNTA	psi-mi:“MI:0914”(association)	0.350
CDC42		psi-mi:“MI:0914”(association)	0.350
FNTA	PPIF	psi-mi:“MI:0914”(association)	0.350
RAB2B	BTAF1	psi-mi:“MI:0914”(association)	0.350
FNTA	YKT6	psi-mi:“MI:0914”(association)	0.350
HEYL	GRAP2	psi-mi:“MI:0914”(association)	0.350
RAB20	BCL10	psi-mi:“MI:0914”(association)	0.350
AKTIP	PGGT1B	psi-mi:“MI:0914”(association)	0.350
RAB2B	SLC27A2	psi-mi:“MI:0914”(association)	0.350
AMMECR1L		psi-mi:“MI:0914”(association)	0.350
FNTA	CHURC1-FNTB	psi-mi:“MI:0914”(association)	0.350
Smad6	DDX1	psi-mi:“MI:0914”(association)	0.350
FNTA	PGGT1B	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (35): PGGT1B (Affinity Capture-MS), PGGT1B (Affinity Capture-MS), PGGT1B (Affinity Capture-MS), PGGT1B (Affinity Capture-MS), PGGT1B (Affinity Capture-MS), PGGT1B (Affinity Capture-MS), PGGT1B (Affinity Capture-MS), PGGT1B (Affinity Capture-MS), FNTA (Two-hybrid), PGGT1B (Affinity Capture-MS), PGGT1B (Positive Genetic), PGGT1B (Affinity Capture-MS), PGGT1B (Affinity Capture-MS), MINA (Affinity Capture-MS), PGGT1B (Phenotypic Enhancement)

ESM2 similar proteins: A0A0E0SP71, A0A348FUE1, A3LQF9, B0G172, C4YSU5, O13782, O80642, O93830, P0DPA1, P18898, P20133, P22007, P32073, P32434, P38604, P41992, P46960, P49355, P49356, P53609, P53610, P53611, P53612, Q02293, Q04782, Q04903, Q08603, Q10231, Q2V0C9, Q38920, Q4WES9, Q54MJ7, Q55D51, Q55D85, Q55DA3, Q55FS0, Q59LF2, Q59M69, Q5E9B3, Q5EAD5

Diamond homologs: B0G172, O13782, O93830, P20133, P41992, P46960, P53609, P53610, P53611, P53612, Q02293, Q08603, Q5E9B3, Q5EAD5, Q84J75, Q8BUY9, Q8K2I1, Q9LHL5, O80642, P32434, P49355, P49356, Q04903, Q38920, Q55DA3, G4MY67, P18898, P22007, Q55D51

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

41 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	35
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1525 predictions. Top by Δscore:

Variant	Effect	Δscore
5:115212418:A:AC	donor_gain	1.0000
5:115212419:C:CC	donor_gain	1.0000
5:115212419:CATT:C	donor_gain	1.0000
5:115212422:T:A	donor_gain	1.0000
5:115212438:AGAGT:A	donor_gain	1.0000
5:115212442:T:TA	donor_gain	1.0000
5:115230969:GTCTT:G	donor_loss	1.0000
5:115230970:TCTTA:T	donor_loss	1.0000
5:115230971:CTTA:C	donor_loss	1.0000
5:115230972:TTA:T	donor_loss	1.0000
5:115230974:A:T	donor_loss	1.0000
5:115230975:C:CG	donor_loss	1.0000
5:115231017:TAGGA:T	acceptor_gain	1.0000
5:115231019:GGA:G	acceptor_gain	1.0000
5:115231022:C:CC	acceptor_gain	1.0000
5:115236381:AGAAC:A	donor_loss	1.0000
5:115236382:GAACT:G	donor_loss	1.0000
5:115236383:AAC:A	donor_loss	1.0000
5:115236384:ACTCA:A	donor_loss	1.0000
5:115236385:CT:C	donor_loss	1.0000
5:115236386:T:TA	donor_loss	1.0000
5:115236387:C:CC	donor_loss	1.0000
5:115236388:ACCA:A	donor_loss	1.0000
5:115236389:C:CT	donor_loss	1.0000
5:115236389:CCATA:C	donor_gain	1.0000
5:115236520:AAA:A	acceptor_gain	1.0000
5:115236523:C:CC	acceptor_gain	1.0000
5:115237852:TCATA:T	donor_loss	1.0000
5:115237853:CATA:C	donor_loss	1.0000
5:115237854:ATAC:A	donor_gain	1.0000

AlphaMissense

2462 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:115212563:C:A	G325W	1.000
5:115212575:G:C	H321D	1.000
5:115216894:C:T	G308E	1.000
5:115216897:C:T	G307E	1.000
5:115216898:C:G	G307R	1.000
5:115216898:C:T	G307R	1.000
5:115221842:C:A	W275C	1.000
5:115221842:C:G	W275C	1.000
5:115221844:A:G	W275R	1.000
5:115221844:A:T	W275R	1.000
5:115221853:A:G	Y272H	1.000
5:115221854:A:C	C271W	1.000
5:115221855:C:T	C271Y	1.000
5:115221856:A:G	C271R	1.000
5:115221860:G:C	D269E	1.000
5:115221860:G:T	D269E	1.000
5:115221861:T:A	D269V	1.000
5:115221861:T:C	D269G	1.000
5:115221861:T:G	D269A	1.000
5:115221862:C:G	D269H	1.000
5:115221869:C:A	K266N	1.000
5:115221869:C:G	K266N	1.000
5:115221878:T:A	R263S	1.000
5:115221878:T:G	R263S	1.000
5:115221879:C:G	R263T	1.000
5:115221882:C:T	G262E	1.000
5:115221916:A:G	W251R	1.000
5:115221916:A:T	W251R	1.000
5:115253227:C:A	G57W	1.000
5:115212553:C:T	G328D	0.999

dbSNP variants (sampled 300 via entrez): RS1000008597 (5:115215653 C>T), RS1000035071 (5:115259418 G>A,C), RS1000068645 (5:115253580 T>C), RS1000073613 (5:115226199 C>A), RS1000091077 (5:115221207 A>G), RS1000134671 (5:115220150 A>C), RS1000153896 (5:115237469 A>C,T), RS1000268961 (5:115237201 G>A), RS1000309096 (5:115204902 T>C), RS1000328052 (5:115242286 G>A), RS1000356523 (5:115253803 C>T), RS1000441195 (5:115253608 T>A), RS1000441965 (5:115208908 C>T), RS1000456180 (5:115238605 A>C), RS1000508380 (5:115238875 G>C)

Disease associations

OMIM: gene MIM:602031 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006658_12	Longevity	9.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2095164 (PROTEIN COMPLEX), CHEMBL2096991 (PROTEIN COMPLEX GROUP), CHEMBL4135 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 19,563 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL289228	TIPIFARNIB	3	18,804
CHEMBL279433	L-778123 FREE BASE	1	324
CHEMBL3218390	GGTI-2418	1	36
CHEMBL351706	BMS-214662	1	399

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

24 measured of 30 human assays (31 total across all organisms); most potent 24 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
4-[3-(4-Cyano-benzyl)-3H-imidazol-4-ylmethyl]-piperazine-1-carboxylic acid adamantan-1-ylamide	IC50	0.2 nM
(5S)-31-oxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.1^{2,5}.1^{15,19}.0^{9,13}.0^{24,28}]hentriaconta-1(27),9,11,15,17,19(30),21(29),22,24(28),25-decaene-18-carbonitrile	IC50	5.5 nM
N-[(S)-1-carbamoyl-2-phenylethyl]-4-[2-(3,4-di-chlorophenyl)-4-(2-methylsulfanylethyl)-5-pyridin-3-yl-2-H-pyrazol-3-yloxy]butyramide	IC50	8.24 nM
(5S)-6-methyl-31-oxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.1^{2,5}.1^{15,19}.0^{9,13}.0^{24,28}]hentriaconta-1(27),9,11,15,17,19(30),21(29),22,24(28),25-decaene-18-carbonitrile	IC50	32 nM
(5R)-31-oxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.1^{2,5}.1^{15,19}.0^{9,13}.0^{24,28}]hentriaconta-1(27),9,11,15,17,19(30),21(29),22,24(28),25-decaene-18-carbonitrile	IC50	35 nM
(5R)-6-methyl-31-oxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.1^{2,5}.1^{15,19}.0^{9,13}.0^{24,28}]hentriaconta-1(27),9,11,15,17,19(30),21(29),22,24(28),25-decaene-18-carbonitrile	IC50	39 nM
N-(adamantan-2-yl)-10-cyano-23-oxo-8-oxa-1,15,17,21-tetraazapentacyclo[19.2.2.1^{3,7}.1^{9,13}.0^{15,19}]heptacosa-3(27),4,6,9(26),10,12,16,18-octaene-4-carboxamide	IC50	43 nM
(5S)-7,31-dioxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.1^{2,5}.1^{15,19}.0^{9,13}.0^{24,28}]hentriaconta-1(27),9,11,15,17,19(30),21(29),22,24(28),25-decaene-18-carbonitrile	IC50	94 nM
(5R)-7,31-dioxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.1^{2,5}.1^{15,19}.0^{9,13}.0^{24,28}]hentriaconta-1(27),9,11,15,17,19(30),21(29),22,24(28),25-decaene-18-carbonitrile	IC50	150 nM
(1R,2R,5R)-30-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaene-17-carbonitrile	IC50	390 nM
(5S)-30-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]triaconta-1(27),8,10,14(29),15,17,20(28),21,23,25-decaene-17-carbonitrile	IC50	650 nM
(23R)-22,23,24,25-Tetrahydro-22-oxo-16H,21H-21,23-ethano-6,10:12,16-dimethenobenz[g]-imidazo[4,3-n][1,9,12,15]oxatriazacycloheneicosine-9-carbonitrile	IC50	810 nM
(1R,2R,5R)-30-oxo-19,24-dioxa-2,6,10,12-tetraazahexacyclo[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaene-17-carbonitrile	IC50	1100 nM
(6R)-27-oxo-2-phenyl-20-oxa-3,7,11,13-tetraazapentacyclo[19.3.1.1^{3,6}.1^{15,19}.0^{9,13}]heptacosa-1(24),9,11,15(26),16,18,21(25),22-octaene-18-carbonitrile	IC50	1600 nM
(5S)-6-methyl-30-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]triaconta-1(27),8,10,14(29),15,17,20(28),21,23,25-decaene-17-carbonitrile	IC50	2200 nM
(1R,2R,5S)-30-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaene-17-carbonitrile	IC50	2200 nM
(5R)-30-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]triaconta-1(27),8,10,14(29),15,17,20(28),21,23,25-decaene-17-carbonitrile	IC50	3900 nM
(1S,2S,5S)-29-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.5.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,26}]nonacosa-8,10,14(28),15,17,20(27),21,23(26)-octaene-17-carbonitrile	IC50	4000 nM
Macrocyclic 3-Aminopyrrolidinone analog 27B	IC50	7000 nM
(6R)-24-bromo-27-oxo-20-oxa-3,7,11,13-tetraazapentacyclo[19.3.1.1^{3,6}.1^{15,19}.0^{9,13}]heptacosa-1(24),9,11,15(26),16,18,21(25),22-octaene-18-carbonitrile	IC50	9200 nM
(1R,2R,5S)-30-oxo-19,24-dioxa-2,6,10,12-tetraazahexacyclo[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaene-17-carbonitrile	IC50	15000 nM
7-hydroxy-11-hydroxymethyl-12-methyl-14,15-dithia-9,12-diazatetracyclo[9.2.2.01,9.03,8]pentadeca-3,5-diene-10,13-dione	IC50	17000 nM
(17R, 20R)-19,20,21,22-Tetrahydro-19-oxo-17H-15,-17:18,20-diethano-6,10:12,16-dimetheno-16H-imidazo[3,4-h][1,8,11,14]oxatriazacycloeicosine-9-carbonitrile	IC50	18000 nM
(1S,2S,5R)-29-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.5.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,26}]nonacosa-8,10,14(28),15,17,20(27),21,23(26)-octaene-17-carbonitrile	IC50	20000 nM

ChEMBL bioactivities

488 potent at pChembl≥5 of 586 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.80	IC50	0.16	nM	CHEMBL64183
9.70	IC50	0.2	nM	CHEMBL424564
9.49	IC50	0.32	nM	CHEMBL63106
9.49	IC50	0.32	nM	CHEMBL63107
9.17	IC50	0.68	nM	CHEMBL291580
9.09	IC50	0.81	nM	CHEMBL322435
9.08	IC50	0.84	nM	CHEMBL303326
8.89	IC50	1.3	nM	CHEMBL75804
8.85	IC50	1.4	nM	CHEMBL99901
8.77	IC50	1.7	nM	CHEMBL159171
8.68	IC50	2.1	nM	CHEMBL157295
8.68	IC50	2.1	nM	CHEMBL450336
8.62	IC50	2.4	nM	CHEMBL158586
8.60	IC50	2.5	nM	CHEMBL316673
8.54	IC50	2.9	nM	CHEMBL318626
8.51	IC50	3.1	nM	CHEMBL24271
8.44	IC50	3.6	nM	CHEMBL294888
8.35	IC50	4.5	nM	CHEMBL2111612
8.32	IC50	4.82	nM	CHEMBL59963
8.32	IC50	4.8	nM	CHEMBL74363
8.32	IC50	4.8	nM	CHEMBL283369
8.30	IC50	5	nM	CHEMBL282103
8.30	IC50	5	nM	CHEMBL60804
8.29	IC50	5.1	nM	CHEMBL102293
8.26	IC50	5.5	nM	CHEMBL80702
8.24	IC50	5.8	nM	CHEMBL1907916
8.15	IC50	7.1	nM	CHEMBL282499
8.14	IC50	7.3	nM	CHEMBL28325
8.14	IC50	7.3	nM	CHEMBL345449
8.14	IC50	7.2	nM	CHEMBL282499
8.10	Ki	8	nM	CHEMBL53670
8.10	IC50	8	nM	CHEMBL329932
8.06	IC50	8.7	nM	CHEMBL418513
8.05	IC50	8.9	nM	CHEMBL415246
8.04	IC50	9.1	nM	CHEMBL304449
8.02	IC50	9.5	nM	CHEMBL283051
8.02	IC50	9.5	nM	GGTI-2418
8.00	IC50	10	nM	CHEMBL24733
8.00	IC50	10	nM	CHEMBL56218
8.00	IC50	10	nM	CHEMBL157551
8.00	IC50	10	nM	CHEMBL100526
7.92	IC50	12	nM	CHEMBL103357
7.89	IC50	13	nM	CHEMBL439047
7.89	IC50	13	nM	CHEMBL319427
7.85	IC50	14	nM	CHEMBL73862
7.81	IC50	15.6	nM	CHEMBL23248
7.80	IC50	16	nM	CHEMBL24554
7.80	IC50	16	nM	CHEMBL23155
7.77	IC50	17	nM	CHEMBL156166
7.77	IC50	17	nM	CHEMBL420273

PubChem BioAssay actives

493 with measured affinity, of 1082 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-(1-adamantyl)-4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxamide	74653: Inhibitory activity against human Geranylgeranyl transferase type I	ic50	0.0002	uM
[2-(trifluoromethoxy)phenyl]methyl 4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxylate	74504: Inhibition of [1-3H]-GGPP incorporation into biotinylated K4B-Ras peptide by geranylgeranyl transferase in the presence of 5 mM ATP	ic50	0.0002	uM
[2-(methoxymethyl)phenyl]methyl 4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxylate	74504: Inhibition of [1-3H]-GGPP incorporation into biotinylated K4B-Ras peptide by geranylgeranyl transferase in the presence of 5 mM ATP	ic50	0.0003	uM
(2-ethoxyphenyl)methyl 4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxylate	74504: Inhibition of [1-3H]-GGPP incorporation into biotinylated K4B-Ras peptide by geranylgeranyl transferase in the presence of 5 mM ATP	ic50	0.0003	uM
(2-chlorophenyl)methyl 4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxylate	74504: Inhibition of [1-3H]-GGPP incorporation into biotinylated K4B-Ras peptide by geranylgeranyl transferase in the presence of 5 mM ATP	ic50	0.0007	uM
4-[(1S)-1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-[(3R)-3-(2-cyclopropylethyl)-1-methyl-2-oxoazepan-3-yl]phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0008	uM
(2-methoxyphenyl)methyl 4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxylate	74504: Inhibition of [1-3H]-GGPP incorporation into biotinylated K4B-Ras peptide by geranylgeranyl transferase in the presence of 5 mM ATP	ic50	0.0008	uM
(2R)-2-[[(3S)-2-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylbutanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]hexanoic acid	74802: In vitro inhibition of Geranylgeranyl transferase type I	ic50	0.0013	uM
4-[(1S)-1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-[(3S)-3-butyl-1-methyl-2-oxoazepan-3-yl]phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0014	uM
4-(2-cyclohexylethyl)-23-oxo-8-oxa-1,15,17,21-tetrazapentacyclo[19.2.2.13,7.19,13.015,19]heptacosa-3,5,7(27),9,11,13(26),16,18-octaene-10-carbonitrile	74798: Inhibition of human Geranylgeranyl transferase type I incorporation of [3H]GGPP into biotinylated peptide corresponding to the C-terminus of human Ki-Ras.	ic50	0.0017	uM
4-[(1S)-1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-[(3R)-3-(cyclopropylmethyl)-1-methyl-2-oxoazepan-3-yl]phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0021	uM
4-(3,3-dimethylbutyl)-23-oxo-8-oxa-1,15,17,21-tetrazapentacyclo[19.2.2.13,7.19,13.015,19]heptacosa-3,5,7(27),9,11,13(26),16,18-octaene-10-carbonitrile	74798: Inhibition of human Geranylgeranyl transferase type I incorporation of [3H]GGPP into biotinylated peptide corresponding to the C-terminus of human Ki-Ras.	ic50	0.0021	uM
4-(2-cyclohexylethynyl)-23-oxo-8-oxa-1,15,17,21-tetrazapentacyclo[19.2.2.13,7.19,13.015,19]heptacosa-3,5,7(27),9,11,13(26),16,18-octaene-10-carbonitrile	74798: Inhibition of human Geranylgeranyl transferase type I incorporation of [3H]GGPP into biotinylated peptide corresponding to the C-terminus of human Ki-Ras.	ic50	0.0024	uM
4-[(1S)-1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-[(3R)-1-methyl-2-oxo-3-(3,3,3-trifluoropropyl)azepan-3-yl]phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0025	uM
4-[(1S)-1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-[(3S)-1-methyl-2-oxo-3-propylazepan-3-yl]phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0029	uM
4-[1-hydroxy-1-(3-methylimidazol-4-yl)-3-phenylprop-2-ynyl]-2-naphthalen-1-ylbenzonitrile	74619: Inhibition of human GGTase-catalyzed incorporation of [3H]GGPP into biotinylated peptide of C-terminal of human K-Ras	ic50	0.0031	uM
4-[(1S)-1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-[(3S)-3-ethyl-1-methyl-2-oxoazepan-3-yl]phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0036	uM
4-[(1S)-1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-[(3R)-3-ethyl-1-methyl-2-oxoazepan-3-yl]phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0045	uM
17-(5,5,5-trifluoropent-1-ynyl)-19-oxa-2,5,10,12-tetrazahexacyclo[18.6.2.22,5.114,18.08,12.023,27]hentriaconta-1(26),8,10,14(29),15,17,20(28),21,23(27),24-decaen-3-one	74649: Inhibition of the human Geranylgeranyl transferase type I catalyzed incorporation of [3H]GGPP into a biotinylated peptide corresponding to the C-terminus of human K-Ras.	ic50	0.0048	uM
[2-(2,2,2-trifluoroethyl)phenyl]methyl 4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxylate	74504: Inhibition of [1-3H]-GGPP incorporation into biotinylated K4B-Ras peptide by geranylgeranyl transferase in the presence of 5 mM ATP	ic50	0.0048	uM
(2R)-2-[[(3S)-2-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3,3-dimethylbutanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-methylsulfanylbutanoic acid	74802: In vitro inhibition of Geranylgeranyl transferase type I	ic50	0.0048	uM
(2S)-2-[[1-[(2R)-2-amino-3-sulfanylpropanoyl]-4-phenylpiperidine-4-carbonyl]amino]-4-methylpentanoic acid	74632: Inhibition of Candida albicans Geranylgeranyl transferase type I	ic50	0.0050	uM
methyl (2S)-2-[[1-[(2R)-2-amino-3-sulfanylpropanoyl]-4-phenylpiperidine-4-carbonyl]amino]-4-methylpentanoate	74632: Inhibition of Candida albicans Geranylgeranyl transferase type I	ic50	0.0050	uM
(2S)-2-[[4-[[(2R)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylpentanoic acid	1121276: Inhibition of human GGTase1 in human Burkitt lymphoma (Daudi) cell supernatant using [3H]geranylgeranyl	ic50	0.0050	uM
4-[1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-(3-ethyl-1-methyl-2-oxoazepan-3-yl)phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0051	uM
31-oxo-20-oxa-2,6,11,13-tetrazahexacyclo[19.6.2.12,5.115,19.09,13.024,28]hentriaconta-1(27),9,11,15(30),16,18,21(29),22,24(28),25-decaene-18-carbonitrile	74628: Inhibitory activity against geranylgeranyl transferase	ic50	0.0055	uM
(5S)-31-oxo-20-oxa-2,6,11,13-tetrazahexacyclo[19.6.2.12,5.115,19.09,13.024,28]hentriaconta-1(27),9,11,15(30),16,18,21(29),22,24(28),25-decaene-18-carbonitrile	1797126: In Vitro FTase Inhibition Assay from Article 10.1021/jm010531d: “3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.”	ic50	0.0055	uM
2-[3-[(3S)-3-ethyl-1-methyl-2-oxoazepan-3-yl]phenoxy]-4-(imidazol-1-ylmethyl)benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0058	uM
2-[3-(3-ethyl-1-methyl-2-oxoazepan-3-yl)phenoxy]-4-(imidazol-1-ylmethyl)benzonitrile	74778: Inhibition of rate of incorporation of [3H]GGPP into a biotinylated peptide corresponding to C-terminus of human Ki-Ras by human geranylgeranyl-transferase type I.	ic50	0.0071	uM
methyl (2S)-2-[[4-[[(2R)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylpentanoate	74648: In vitro inhibition of [3H]GGPP incorporation into H-Ras-CVLL by Geranylgeranyl transferase type I	ic50	0.0073	uM
3-sulfanylpropyl (2R)-2-(2,3-dihydro-1H-indene-2-carbonylamino)-3-naphthalen-1-ylpropanoate	74494: Tested for the inhibition of Candida GGTase I in Candida albicans	ic50	0.0073	uM
propan-2-yl (2S)-2-[[2-[2-(4-fluorophenyl)ethyl]-5-[[(2S,4S)-4-(pyridine-3-carbonylsulfanyl)pyrrolidin-2-yl]methylamino]benzoyl]amino]-4-methylsulfanylbutanoate	74790: Inhibition binding constant against Geranylgeranyl transferase type I	ki	0.0080	uM
4-[amino-(3-methylimidazol-4-yl)methyl]-2-[3-(3-ethyl-1-methyl-2-oxoazepan-3-yl)phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0080	uM
N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-4-[1-(3,4-dichlorophenyl)-4-(2-methylsulfanylethyl)-3-pyridin-3-ylpyrazol-5-yl]oxybutanamide	1797274: In Vitro FTase/GGTase-1 Inhibition Assay from Article 10.1074/jbc.M600168200: “A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.”	ic50	0.0082	uM
(2-ethoxy-3-pyridinyl)methyl 4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxylate	74504: Inhibition of [1-3H]-GGPP incorporation into biotinylated K4B-Ras peptide by geranylgeranyl transferase in the presence of 5 mM ATP	ic50	0.0087	uM
2-[3-(1-acetyl-3-ethylazepan-3-yl)phenoxy]-4-(imidazol-1-ylmethyl)benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0089	uM
(2-methylphenyl)methyl 4-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]piperazine-1-carboxylate	74506: Inhibition of [1-3H]-GGPP incorporation into biotinylated K4B-Ras peptide by geranylgeranyl transferase in the presence of 5 mM ATP	ic50	0.0091	uM
(2S)-2-[[(2S)-2-benzyl-4-[(5-methyl-1H-imidazol-4-yl)methyl]-3-oxopiperazine-1-carbonyl]amino]-4-methylpentanoic acid	1121276: Inhibition of human GGTase1 in human Burkitt lymphoma (Daudi) cell supernatant using [3H]geranylgeranyl	ic50	0.0095	uM
4-[3-(4-chlorophenyl)-1-hydroxy-1-(3-methylimidazol-4-yl)prop-2-ynyl]-2-naphthalen-1-ylbenzonitrile	74619: Inhibition of human GGTase-catalyzed incorporation of [3H]GGPP into biotinylated peptide of C-terminal of human K-Ras	ic50	0.0095	uM
N-[(2R)-3-(3,4-dichlorophenyl)-1-[2-(1H-imidazol-5-yl)ethylamino]-1-oxopropan-2-yl]-9H-xanthene-9-carboxamide	74494: Tested for the inhibition of Candida GGTase I in Candida albicans	ic50	0.0100	uM
2-[3-(3-ethyl-1-methyl-2-oxoazepan-3-yl)phenoxy]-4-[(3-methylimidazol-4-yl)methyl]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0100	uM
4-[3-(4-cyanophenyl)-1-hydroxy-1-(3-methylimidazol-4-yl)prop-2-ynyl]-2-naphthalen-1-ylbenzonitrile	74619: Inhibition of human GGTase-catalyzed incorporation of [3H]GGPP into biotinylated peptide of C-terminal of human K-Ras	ic50	0.0100	uM
(2S)-2-[[(2S)-2-[[1-[(2R)-2-amino-3-sulfanylpropanoyl]-4-phenylpiperidine-4-carbonyl]amino]-4-methylpentanoyl]amino]propanoic acid	74632: Inhibition of Candida albicans Geranylgeranyl transferase type I	ic50	0.0100	uM
2-[3-(3-ethyl-1-methyl-2-oxoazepan-3-yl)phenoxy]-4-(1H-imidazol-5-ylmethyl)benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0120	uM
2-[3-(3-ethyl-1-methyl-2-oxoazepan-3-yl)phenoxy]-4-[1-hydroxy-1-(3-methylimidazol-4-yl)ethyl]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0130	uM
4-[(1R)-1-amino-1-(3-methylimidazol-4-yl)ethyl]-2-[3-[(3S)-3-ethyl-1-methyl-2-oxoazepan-3-yl]phenoxy]benzonitrile	74654: Concentration required to inhibit recombinant human geranylgeranyl transferase type I (GGTase-I) catalyzed incorporation of [3H]GGPP to the C-terminus of human K-Ras.	ic50	0.0130	uM
(2R)-2-[[(3S)-2-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3,3-dimethylbutanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-methylsulfonylbutanoic acid	74802: In vitro inhibition of Geranylgeranyl transferase type I	ic50	0.0140	uM
17-[4-(trifluoromethyl)phenyl]-19-oxa-2,5,10,12-tetrazahexacyclo[18.6.2.22,5.114,18.08,12.023,27]hentriaconta-1(26),8,10,14(29),15,17,20(28),21,23(27),24-decaen-3-one	74649: Inhibition of the human Geranylgeranyl transferase type I catalyzed incorporation of [3H]GGPP into a biotinylated peptide corresponding to the C-terminus of human K-Ras.	ic50	0.0156	uM
4-[3-(4-ethynylphenyl)-1-hydroxy-1-(3-methylimidazol-4-yl)prop-2-ynyl]-2-naphthalen-1-ylbenzonitrile	74619: Inhibition of human GGTase-catalyzed incorporation of [3H]GGPP into biotinylated peptide of C-terminal of human K-Ras	ic50	0.0160	uM
3-oxo-19-oxa-2,5,10,12-tetrazahexacyclo[18.6.2.22,5.114,18.08,12.023,27]hentriaconta-1(26),8,10,14(29),15,17,20(28),21,23(27),24-decaene-17-carbonitrile	74649: Inhibition of the human Geranylgeranyl transferase type I catalyzed incorporation of [3H]GGPP into a biotinylated peptide corresponding to the C-terminus of human K-Ras.	ic50	0.0160	uM

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression	2
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression, affects cotreatment	1
trichostatin A	affects expression	1
sodium arsenite	increases expression	1
ochratoxin A	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
CC-8490	increases expression	1
bisphenol S	affects cotreatment, increases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Arsenic Trioxide	decreases expression	1
Air Pollutants	increases abundance, decreases expression	1
Cadmium	increases abundance, increases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Hydrogen Peroxide	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Lipopolysaccharides	decreases reaction, increases phosphorylation, increases secretion	1
Plant Extracts	affects cotreatment, increases expression	1
Tamoxifen	increases expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Urethane	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1

ChEMBL screening assays

141 unique, capped per target: 121 binding, 20 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1260645	Binding	Inhibition of human geranylgeranyltransferase-1 assessed as incorporation of [3H]GGPP into H-Ras-CVLL	Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. — J Med Chem
CHEMBL681665	Functional	Inhibition of geranylgeranylation of C-terminal CAAX sequence of Rap 1a in PSN-1 cells	The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.